Modality
Bispecific Ab
MOA
VEGFi
Target
BCMA
Pathway
PI3K/AKT
LNNB
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
~Apr 2024
→ ~Jul 2025
Phase 2
Oct 2025
→ Jul 2025
Phase 2Current
NCT03009997
455 pts·LN
2025-10→2025-07·Recruiting
455 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-278mo agoPh2 Data· LN
2026-01-083mo agoEnrollment Complete· NB
Trial Timeline
Q3Q42026
P2
Recruit…
Catalysts
Ph2 Data
2025-07-27 · 8mo ago
LN
Enrollment Complete
2026-01-08 · 3mo ago
NB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03009997 | Phase 2 | LN | Recruiting | 455 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |